Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Certara’s Synchrogenix Division Named to the 2016 Inc. 5000 List of the Fastest-growing Private Companies in America

PRINCETON, NJ – Aug. 29, 2016 – Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that Synchrogenix, its medical and regulatory writing consultancy, has been named to the 2016 Inc. 5000 list of the fastest-growing private companies in America.

Solution: Regulatory & Medical Writing
More Info

Certara Acquires Specialty Contract Research Organization Synchrogenix

Purchase adds global regulatory writing and submission services to Certara’s drug development consulting expertise ST. LOUIS, MO – April 15, 2014 – Certara™, the leading technology-enabled drug development and drug safety consultancy, announced today that it has acquired specialty contract research organization (CRO) Synchrogenix Information Strategies Inc. Synchrogenix offers regulatory writing and related services to […]

More Info

Synchrogenix & CISCRP Partner to Help Biopharm Companies Meet Clinical Data Transparency Mandates

The Center for Information and Study on Clinical Research Participation (CISCRP) and Synchrogenix, Certara’s regulatory writing consultancy, are collaborating to develop lay summaries of clinical trials for the general public PRINCETON, NJ – April 23, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy and the nonprofit Center for Information and Study of Clinical […]

More Info

Synchrogenix, Certara’s Regulatory and Medical Writing Consultancy, Acquires ClinGenuity

Deal provides Synchrogenix with proprietary technology, expert staff, and new capabilities to become the dominant player in life science regulatory and medical writing PRINCETON, NJ – Jan. 6, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that its regulatory and medical consultancy, Synchrogenix, has acquired ClinGenuity, the […]

More Info

Certara’s Synchrogenix Division and PleaseTech Partner to Streamline Document Redaction Services

PRINCETON, NJ – Aug. 4, 2016 – Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that its regulatory and medical consultancy, Synchrogenix, is partnering with document co-authoring and collaborative review specialist PleaseTech Ltd. to deliver a seamless regulatory document creation process.

Solution: Regulatory & Medical Writing
More Info

Certara’s ClinGenuity Named a “Cool Vendor” in Gartner’s 2015 Life Sciences Report

PRINCETON, NJ – Apr. 30, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that its ClinGenuity company has been named a “Cool Vendor” in Gartner, Inc.’s 2015 Life Sciences report1. ClinGenuity was acquired by Synchrogenix, Certara’s regulatory writing company, in January 2015. “We are delighted that Gartner has recognized us,” said […]

More Info

A Streamlined Approach to Policy 70

David Cornwell, Founder and CEO of PleaseTech and Lora Killian, Synchrogenix Director of Transparency and Disclosure, provided an in-depth review of the full streamlined process created as a result of the partnership between Synchrogenix and PleaseTech.

Speaker(s): David Cornwell, Lora Killian
Solution: Clinical Transparency & Disclosure, Regulatory & Medical Writing
More Info

Aaron Bernstein Appointed to Group Updating Guidelines on Clinical Study Protocols and Reports

Dr. Bernstein will work with the Budapest Working Group to update International Conference on Harmonisation guidelines for developing clinical study protocols and reports PRINCETON, NJ – Mar. 19, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that Aaron Bernstein, Ph.D., director of global submissions for Synchrogenix, its […]

More Info
Learn More
LinkedIn